Xbrane Biopharma AB
STO:XBRANE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xbrane Biopharma AB
STO:XBRANE
|
SE |
|
Agency Group Australia Ltd
ASX:AU1
|
AU |
|
Odawara Engineering Co Ltd
TSE:6149
|
JP |
|
V
|
Vizsla Silver Corp
AMEX:VZLA
|
CA |
|
Saratoga Investment Corp
NYSE:SAR
|
US |
|
Q
|
Qibu Corp Ltd
SSE:603557
|
CN |
|
F
|
Facor Alloys Ltd
BSE:532656
|
IN |
|
F
|
Formosa Taffeta Co Ltd
TWSE:1434
|
TW |
|
Indian Terrain Fashions Ltd
NSE:INDTERRAIN
|
IN |
|
Innotech Corp
TSE:9880
|
JP |
|
HB Fuller Co
NYSE:FUL
|
US |
|
Netmarble Corp
KRX:251270
|
KR |
|
Shenzhen AV-Display Co Ltd
SZSE:300939
|
CN |
|
V
|
Vietnam Germany Steel Pipe JSC
VN:VGS
|
VN |
|
K
|
Kerur Holdings Ltd
TASE:KRUR
|
IL |
|
Lee Chi Enterprises Co Ltd
TWSE:1517
|
TW |
|
Fino Payments Bank Ltd
NSE:FINOPB
|
IN |
|
Media Links Co Ltd
TSE:6659
|
JP |
|
Oswal Agro Mills Ltd
NSE:OSWALAGRO
|
IN |
|
A
|
Acelon Chemicals & Fiber Corp
TWSE:1466
|
TW |
|
Velo3D Inc
NASDAQ:VELO
|
US |
Xbrane Biopharma AB
Xbrane Biopharma AB is a biopharmaceutical company, which engages in the development and manufacture of biosimilars. The company is headquartered in Solna, Stockholm. The company went IPO on 2016-02-03. The company develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The firm's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Xbrane Biopharma AB is a biopharmaceutical company, which engages in the development and manufacture of biosimilars. The company is headquartered in Solna, Stockholm. The company went IPO on 2016-02-03. The company develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The firm's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
